Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis

What Was Tested

The paper reports a study of Leuprolide in the context of chronic and systemic inflammation and chronic pain: fibromyalgia & crps, published as a randomized controlled trial.

Who Took Part

PubMed indexes the participants as teenagers and adults, women only.

Eighty-two women, 18 to 40 years of age (mean 30 years), with endometriosis, dysmenorrhoea and/or CPP, were randomized using a computer-generated system of sealed envelopes into either LNG-IUS (n = 39) or GnRH analogue (n = 43) treatment groups at three university centres.

The pain score diary was based on the VAS in which women recorded the occurrence and intensity of pain on a daily basis.

How the Study Was Run

The researchers set it up as a randomized and multicenter study.

The participants were allocated by chance, so the Leuprolide group and the comparison group should start out alike.

More than one site took part, so the participants came from several places.

A monthly score was calculated from the result of the sum of the daily scores divided by the number of days in each observation period.

What Was Measured

Topics PubMed links to this paper include Endometriosis, Gonadotropin-Releasing Hormone, Intrauterine Devices, Medicated, Leuprolide, Levonorgestrel and Pelvic Pain.

What This Means in Plain Language

The paper is a randomized and multicenter study of Leuprolide in people with chronic and systemic inflammation.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2005 (Human reproduction (Oxford, England)), a journal based in England.

More context: the Leuprolide compound page, Chronic and systemic inflammation research, Chronic pain: fibromyalgia & CRPS research.